Dr. Stefan Roberts is the Founder and CEO of inSoma Bio, where he has led the translation of a Duke University biomaterials discovery into a clinical-stage regenerative medicine platform. He has guided Fractomer™ from early laboratory work through preclinical validation and into FDA-regulated clinical development, securing over $15M funding, including $6M in competitive SBIR/STTR funding. Dr. Roberts has worked in biomaterials design, protein engineering, and translational tissue engineering for over 15 years. He earned a B.S. in Biomedical Engineering from Washington University in St. Louis and a Ph.D. from Duke University, where he developed the foundational technology that became inSoma Bio. His motivation to translate scientific innovation into clinical practice stems from formative roles at St. Jude Children’s Research Hospital and Barnes-Jewish Hospital.